Presented by Dr Laetitia Collet (Institut Jules Bordet, Brussels Belgium)
The phase II LORELEI clinical trial evaluated the efficacy of taselisib, a β-sparing PI3K inhibitor, in combination with letrozole versus placebo plus letrozole as neoadjuvant therapy in postmenopausal women with early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer. Initial results published in Lancet Oncology demonstrated an improved overall response rates (ORR) with taselisib in both the intention-to-treat population and in patients harboring a PIK3CA mutations. In a comprehensive translational research effort, Dr Laetitia Collet, medical oncologist at the Institut Jules Bordet in Brussels, explored biomarkers of response to taselisib, focusing on PIK3CA mutation type, histological subtype, and the tumor microenvironment.
First, the PIK3CA mutational landscape revealed distinct predictive value based on mutation domain. A statistically significant increase in ORR was observed in patients with helical-domain PIK3CA mutations, with the E542K mutation exhibiting the strongest association (80% ORR with taselisib versus 10% in the placebo arm). In contrast, patients with kinase-domain PIK3CA mutations did not demonstrate benefit from taselisib. Transcriptomic analysis indicated enhanced PI3K-AKT-mTOR pathway activity in tumors with helical-domain mutations, providing a mechanistic rationale for this observed differential response.
In addition, also the histological subtype significantly influenced treatment response. Lobular breast cancers demonstrated >60% ORR with taselisib irrespective of PIK3CA mutation status, whereas benefit in non-special type (NST) tumors was restricted to cases harboring PIK3CA mutations. Importantly, lobular tumors showed constitutive activation of PI3K-AKT-mTOR signaling regardless of mutation status. Additionally, these tumors were enriched for M2-polarized macrophages, suggestive of an immunosuppressive microenvironment. Single-cell RNA sequencing data revealed that myeloid cells, including macrophages, express high levels of PI3K-AKT-mTOR signaling components, supporting the hypothesis that taselisib may reprogram macrophages via PI3Kγ inhibition, enhancing antitumor immunity.
Collectively, these findings highlight the potential of taselisib to exert dual antitumor effects: direct tumor suppression via PI3Kα inhibition and modulation of the tumor immune microenvironment via PI3Kγ blockade. These insights may guide future biomarker-driven patient selection and combination strategies in HR+ breast cancer.
References:
Collet L, et al. ESMO 2025; Abstract 116MO.
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in